Search EN menu en EIB GROUP CLIENT PORTAL
Close EIB GROUP CLIENT PORTAL
Search
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

MEDI-SCIENCE R&D FRAMEWORK (I2I)

Signature(s)

Amount
€ 226,334,388.76
Countries
Sector(s)
Germany : € 226,334,388.76
Services : € 113,167,194.38
Industry : € 113,167,194.38
Signature date(s)
13/07/2005 : € 20,500,000
13/07/2005 : € 20,500,000
13/07/2005 : € 44,667,194.38
13/07/2005 : € 44,667,194.38
15/09/2005 : € 48,000,000
15/09/2005 : € 48,000,000
Link to source
Data sheet
MEDI-SCIENCE R&D FRAMEWORK (I2I)
Other links
Summary sheet
Medi-Science R & D Framework (i2i)

Summary sheet

Release date
16 June 2004
Status
Reference
Signed | 13/07/2005
20030508
Project name
Promoter - financial intermediary
Medi-Science R & D Framework (i2i)
Fresenius – The Health Care Group.
Proposed EIB finance (Approximate amount)
Total cost (Approximate amount)
EUR 232m.
Up to EUR 330m.
Location
Sector(s)
Description
Objectives

The project concerns the promoter’s Research and Development expenditures in medical care and biotechnology (antibodies and cell therapy) and upgrading of existing manufacturing facilities for dialysis and products.

The research activities aim at the innovation of high-quality products and new therapy approaches in line with the Bank’s Innovation 2010 Initiative. The promoter’s main production facilities in dialysis technology are located in Objective 2 areas for allocations from the EU Structural Fund. The project will result in creation of some new jobs while safeguarding existing employment.

Environmental aspects
Procurement

Compliance with EU environmental directives and national laws shall be ensured.

Procurement regulations do not apply to this private industry project. The promoter carries out competitive enquiries among potential suppliers for goods and services, as is usual in the industry.

Comments

Fabrication of medical equipment and pharmaceuticals.

Link to source
Summary sheet
Medi-Science R & D Framework (i2i)
Other links
Data sheet
MEDI-SCIENCE R&D FRAMEWORK (I2I)

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
Alternatively, the EIB can be contacted through its external offices.
Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

Media enquiries

Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero tolerance against fraud and corruption

The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Investigations Division. All reports will be treated as strictly confidential and handled in line with EIB investigation procedures and the EIB Group Anti-Fraud Policy.

Related publications